Search

Michael Schäfers

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving $^textrm177$ Lu-PSMA-617 Radioligand Therapy

Published with Wowchemy — the free, open source website builder that empowers creators.